1. News
  2. IRB Barcelona researcher Roger Gomis receives an award for his work on cancer

IRB Barcelona researcher Roger Gomis receives an award for his work on cancer

Roger Gomis, head of the Growth Control and Cancer Metastasis Lab

Roger Gomis, head of the Growth Control and Cancer Metastasis Lab
2 Nov 2018

The Spanish Association of Cancer Research recognizes his work and grants him the ASEICA Young Investigator Award 2018.

The award ceremony will be held in Valencia on 6, 7 and 8 November.

The Spanish Association for Research on Cancer (ASEICA) has announced the winners of the 2018 ASEICA Awards, among them Roger Gomis, head of the Growth Control and Metastasis  lab at IRB Barcelona, who has received the Young Investigator Award in acknowledgement of his work on cancer.

ICREA researcher Roger Gomis leads a multidisciplinary lab devoted to metastasis research at IRB Barcelona. His work focuses on the identification and functional validation of the mechanisms that allow breast and colon cancer to metastasize to clinically relevant sites, and he has published various important articles in recent years.

“These awards aim to acknowledge the magnificent work that Spanish scientists are doing in spite of insufficient resources in the country,” said Carlos Camps, president of ASEICA.

The projects of the awardees will be presented in Valencia on 6,7 and 8 November in a gathering that will serve to disseminate advances in cancer research, present the most recent studies in the field, and showcase the work being undertaken on different types of tumour.

 

More information: http://www.aseica.es/

 

If you want to know more about the research that Roger Gomis lab does, you can watch the Meet Our Scientists Video "Light and credibility": https://www.youtube.com/watch?v
 

 

About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 25 laboratories and seven core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and 32 nationalities. It is located in the Barcelona Science Park. IRB Barcelona forms part of the Barcelona Institute of Science and Technology (BIST) and the “Xarxa de Centres de Recerca de Catalunya” (CERCA).

cancer
metastasis
breast cancer
award

Related content

News

<p>Image: SINC</p>

The origin of cancer: a magnifying glass to investigate the Big Bang tumor

SINC, El Público, Catalunya Vanguardista and the newspaper Heraldo de Aragón, have published an article about the process and conditions that triggers cancer according to a study published in the journal Science that raises new theories about aging. The article includes the opinion of Salvador Aznar Benitah, ICREA researcher at IRB Barcelona, about the study: "it is a very well done piece of work, with a very sophisticated analysis. We tend to think that the tumour tissue has mutations and the healthy one does not, but that is not the case.

Donate to the medicine of the future

Coinciding with #GivingTuesday, today IRB Barcelona is launching its donation campaign for the forthcoming holiday season.

Basic research paves the way towards the medicine of the future. Donations made to research speed up discoveries

<p>Roger Gomis, head of the Growth Control and Cancer Metastasis Lab</p>

A new weapon in the fight against metastasis

The “Dinero” supplement of the newspaper La Vanguardia has interviewed Roger Gomis, ICREA researcher at IRB Barcelona, about Inbiomotion, a spin-off from the institute and ICREA. This company, which came about from biomedical research and an entrepreneurial spirit, develops and commercialises a diagnostic test that allows the identification of those breast cancer patients most likely to develop bone metastasis.